Table 4.
Patient-oncologist matching items
| Patients | Oncs | Diff (%) | |
|---|---|---|---|
| (1) The switch to biosimilar trastuzumab was explained in an easily understood way | 42.3% (63/149) | 57.6% (19/33) | 15.3 |
| (2) The patient felt involved in this treatment decision to use biosimilar trastuzumab | 18.4% (28/152) | 18.2% (6/33) | − 0.2 |
| (3) The oncologist is trusted to make the right decision about using biosimilar trastuzumab | 62.6% (92/147) | 66.7% (22/33) | 4.1 |
| (4) The insurance company is trusted to make the right decision about using biosimilar trastuzumab | 9.3% (14/150) | 12.1% (4/33) | 2.8 |
| (5) The hospital/center is trusted to make the right decision about using biosimilar trastuzumab | 41.3% (59/143) | 44.1% (15/34) | 2.9 |
| (6) The patient had the opportunity to ask questions about a switch to biosimilar trastuzumab | 35.3% (54/153) | 58.8% (20/34) | 23.5 |
| (7) The patient was given adequate resources about biosimilar trastuzumab to feel comfortable with this switch | 17.6% (27/153) | 33.3% (11/33) | 15.7 |
| (8) The cancer is/will be treated as effectively with biosimilar trastuzumab | 43.4% (62/143) | 79.4% (27/34) | 36.1 |
| (9) The patient understands the reason for this switch to biosimilar trastuzumab | 42.6% (63/148) | 39.4% (13/33) | -3.2 |
| (10) The patient is worried about this switch to biosimilar trastuzumab (r) | 23.6% (35/148) | 41.2% (13/34) | 17.5 |
| (11) The patient has emotionally adjusted to this treatment switch that wasn’t due to cancer progression or quality of life issues | 41.0% (59/144) | 42.4% (14/33) | 1.5 |
| (12) The patient worries more about treatment success since this switch to biosimilar trastuzumab (r) | 29.1% (43/148) | 33.3% (11/33) | 4.3 |
| (13) Switching to a biosimilar trastuzumab is a minor change in the patient’s care | 36.6% (53/145) | 66.7% (22/33) | 30.1 |
| (r) reverse coded items |